Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis

Abstract

Body surface area-based dosing of i.v. golimumab was well tolerated and provided adequate PK exposure for clinical efficacy in paediatric patients with active pc-JIA.ClinicalTrials.gov number NCT02277444.